MM-120

Mind Medicine's MM120, an optimized LSD formulation, demonstrates significant anxiety symptom reduction in Phase 2b trials for generalized anxiety disorder, advancing to Phase 3 testing.

Cybin Inc. highlights positive Phase 2 data for CYB003, showing significant efficacy in treating major depressive disorder (MDD).

4DMT is focusing its pipeline on 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis, leveraging their strong clinical proof of concept.

The FDA has issued draft guidance to assist sponsors in developing psychedelic drugs for psychiatric disorders, substance use disorders, and other medical conditions.

MindMed's MM120, an orally disintegrating tablet form of LSD, is progressing through Phase III trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD).